Predictive factors for acute symptomatic esophagitis in 256 patients with locally advanced non-small cell lung cancer treated with intensity-modulated radiation therapy
*Department of Radiation Oncology,Cancer Hospital,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences,Peking Union Medical College,Beijing 100021,China
Abstract：Objective To explore the incidence and related predictive factors for acute symptomatic esophagitis in patients with locally advanced non-small cell lung cancer (NSCLC) treated with intensity-modulated radiation therapy (IMRT). Methods Data were collected retrospectively from 256 patients with inoperable or unresectable stage Ⅲ NSCLC treated in our hospital between January 2007 and December 2011.The radiotherapy target volume included primary lung cancer and lymphatic drainage area involved, with a median dose of 60 Gy in 30 fractions (50－70 Gy).Of all the patients, 109 patients (42.6%) received concurrent chemotherapy. Grade ≥2 acute esophagitis (AE)(symptomatic esophagitis) which occurred during radiotherapy and within 3 months after completion of radiotherapy served as the outcome event. National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0(NCI-CTCAE3.0) was used to evaluate the grade of AE.The logistic regression model was used to analyze the predictive factors. Results A total of 174 patients (68%) had treatment-related grade ≥2 AE;154 patients (60.2%) had grade 2 AE and 20 patients (7.8%) had grade 3 AE.The median dose when grade ≥2 AE occurred was 30 Gy (11-68 Gy).For grade ≥2 AE, multivariate analysis showed that esophageal V5-V60, mean dose, and age were independent predictive factors (P=0.021, 0, 0.010).For grade ≥3 AE, multivariate analysis showed that esophageal V50-V60, concurrent chemotherapy, and body mass index (BMI) were independentpredictivefactors (P=0.010, 0.003, 0.019).Old age and higher BMI were the protective factors for grade ≥2 and≥3 AE, respectively. Conclusions For patients with locally advanced NSCLC treated with IMRT, esophageal V50—V60 and concurrent chemotherapy are predictive factors for grade ≥3 AE, and esophageal V50 has a high predictive value for both grade ≥2 and ≥3 AE.
Sun Shuai,Wang Jingbo,Ji Zhe et al. Predictive factors for acute symptomatic esophagitis in 256 patients with locally advanced non-small cell lung cancer treated with intensity-modulated radiation therapy[J]. Chinese Journal of Radiation Oncology, 2015, 24(6): 605-609.
[1] Rosenzweig KE,Fox JL,Yorke E,et al. Results of a phase I dose-escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable non-small-cell lung carcinoma[J].Cancer,2005,103(10):2118-2127.DOI:10.1002/cncr.21007. [2] Rodrigues G,Lock M,D′Souza D,et al. Prediction of radiation pneumonitis by dose-volume histogram parameters in lung cancer-a systematic review[J].Radiother Oncol,2004,71(2):127-138.DOI:10.1016/j.radonc.2004.02.015. [3] Kong FM,Ten Haken R,Eisbruch A,et al. Non-small cell lung cancer therapy-related pulmonary toxicity:an update on radiation pneumonitis and fibrosis[J].Semin Oncol,2005,32(Suppl 3):42-54.DOI:10.1053/j.seminoncol.2005.03.009. [4] Kong FM,Hayman JA,Griffith KA,et al. Final toxicity results of a radiation-dose escalation study in patients with non-small-cell lung cancer (NSCLC):predictors for radiation pneumonitis and fibrosis[J].Int J Radiat Oncol Biol Phys,2006,65(4):1075-1086.DOI:10.1016/j.ijrobp.2006.01.051. [5] 朱向帜,王绿化,王颖杰,等.三维适形放疗局部晚期非小细胞肺癌的放射性肺炎风险因素研究[J].中华放射肿瘤学杂志,2007,16(6):421-426.DOI:10.3760/j.issn:1004-4221.2007.06.004. [6] 王澜,李晓宁,吕冬婕,等.肺低剂量区体积预测急性放射性肺炎价值探讨[J].中华放射肿瘤学杂志,2010,19(4):296-300.DOI:10.3760/cma.j.issn.1004-4221.2010.04.005. [7] 王静波,曹建忠,姬巍,等.局部晚期非小细胞肺癌三维放疗后放射性肺损伤风险因素分析[J].中华放射肿瘤学杂志,2012,21(2):114-120.DOI:10.3760/cma.j.issn.1004-4221.2012.02.006. [8] Robnett TJ,Machtay M,Vines EF,et al. Factors predicting severe radiation pneumonitis in patients receiving definitive chemoradiation for lung cancer[J].Int J Radiat Oncol Biol Phys,2000,48(1):89-94.DOI:10.1016/S0360-3016(00)00648-9. [9] Dehing-Oberije C,De Ruysscher D,Van Baardwijk A,et al. The importance of patient characteristics for the prediction of radiation-induced lung toxicity[J].Radiother Oncol,2009,91(3):421-426.DOI:10.1016/j.radonc.2008.12.002. [10] Wang JB,Cao JZ,Yuan SH,et al. Poor baseline pulmonary function may not increase the risk of radiation-induced lung toxicity[J].Int J Radiat Oncol Biol Phys,2013,85(3):798-804.DOI:10.1016/j.ijrobp.2012.06.040. [11] Hernando ML,Marks LB,Bentel GC,et al. Radiation-induced pulmonary toxicity:a dose-volume histogram analysis in 201 patients with lung cancer[J].Int J Radiat Oncol Biol Phys,2001,51(3):650-659.DOI:10.1016/S0360-3016(01)01685-6. [12] Hope AJ,Lindsay PE,El Naqa I,et al. Modeling radiation pneumonitis risk with clinical,dosimetric,and spatial parameters[J].Int J Radiat Oncol Biol Phys,2006,65(1):112-124.DOI:10.1016/j.ijrobp.2005.11.046. [13] Rancati T,Ceresoli GL,Gagliardi G,et al. Factors predicting radiation pneumonitis in lung cancer patients:a retrospective study[J].Radiother Oncol,2003,67(3):275-283.DOI:10.1016/S0167-8140(03)00119-1. [14] Marks LB,Bentzen SM,Deasy JO,et al. Radiation dose-volume effects in the lung[J].Int J Radiat Oncol Biol Phys,2010,76(3 Suppl):S70-76.DOI:10.1016/j.ijrobp.2009.06.091. [15] Palma DA,Senan S,Tsujino K,et al. Predicting radiation pneumonitis after chemoradiation therapy for lung cancer:an international individual patient data meta-analysis[J].Int J Radiat Oncol Biol Phys,2013,85(2):444-450.DOI:10.1016/j.ijrobp.2012.04.043. [16] Wang LH,Wu SX,Ou GF,et al. Randomized phase Ⅱ study of concurrent cisplatin/etoposide or paclitaxel/carboplatin and thoracic radiotherapy in patients with stage Ⅲ non-small cell lung cancer[J].Lung Cancer,2012,77(1):89-96.DOI:10.1016/j.lungcan.2012.02.011. [17] Perrier L,Buja A,Mastrangelo G,et al. Transferability of health cost evaluation across locations in oncology:cluster and principal component analysis as an explorative tool[J].BMC Health Serv Res,2014,14:537.DOI:10.1186/s12913-014-0537-x. [18] Guo JJ,Jing YH,Nguyen K,et al. Principal components analysis of drug expenditure and utilisation trends for major therapeutic classes in US Medicaid programmes[J].J Med Econ,2008,11(4):671-694.DOI:10.3111/13696990802579966. [19] Holmes GM,Pink GH.Adoption and perceived effectiveness of financial improvement strategies in critical access hospitals[J].J Rural Health,2012,28(1):92-100.DOI:10.1111/j.1748-0361.2011.00368.x. [20] Ding C,He XF.K-means clustering via principal component analysis[A]//Proceeding ICML’04:Proceedings of the 21th International Conference on Machine Learning[C].New York:ACM,2004.DOI:10.1145/1015330.1015408. [21] Dang J,Li G,Ma LH,et al. Predictors of grade ≥ 2 and grade ≥ 3 radiation pneumonitis in patients with locally advanced non-small cell lung cancer treated with three-dimensional conformal radiotherapy[J].Acta Oncol,2013,52(6):1175-1180.DOI:10.3109/0284186X.2012.747696. [22] Song CH,Pyo H,Moon SH,et al. Treatment-related pneumonitis and acute esophagitis in non-small-cell lung cancer patients treated with chemotherapy and helical tomotherapy[J].Int J Radiat Oncol Biol Phys,2010,78(3):651-658.DOI:10.1016/j.ijrobp.2009.08.068. [23] Yom SS,Liao ZX,Liu HH,et al. Initial evaluation of treatment-related pneumonitis in advanced-stage non-small-cell lung cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy[J].Int J Radiat Oncol Biol Phys,2007,68(1):94-102.DOI:10.1016/j.ijrobp.2006.12.031. [24] Shi AH,Zhu GY,Wu H,et al. Analysis of clinical and dosimetric factors associated with severe acute radiation pneumonitis in patients with locally advanced non-small cell lung cancer treated with concurrent chemotherapy and intensity-modulated radiotherapy[J].Radiat Oncol,2010,5:35.DOI:10.1186/1748-717X-5-35. [25] Seppenwoolde Y,Lebesque JV,de Jaeger K,et al. Comparing different NTCP models that predict the incidence of radiation pneumonitis. Normal tissue complication probability[J].Int J Radiat Oncol Biol Phys,2003,55(3):724-735.DOI:10.1016/S0360-3016(02)03986-X. [26] Yorke ED,Jackson A,Rosenzweig KE,et al. Correlation of dosimetric factors and radiation pneumonitis for non-small-cell lung cancer patients in a recently completed dose escalation study[J].Int J Radiat Oncol Biol Phys,2005,63(3):672-682.DOI:10.1016/j.ijrobp.2005.03.026. [27] Kim Y,Hong SE,Kong M,et al. Predictive factors for radiation pneumonitis in lung cancer treated with helical tomotherapy[J].Cancer Res Treat,2013,45(4):295-302.DOI:10.4143/crt.2013.45.4.295. [28] 姬巍,王绿化,欧广飞,等.非小细胞肺癌术后适形放疗肺损伤相关因素研究[J].中华放射肿瘤学杂志,2009,18(4):274-277.DOI:10.3760/cma.j.issn.1004-4221.2009.04.274.
2015, Vol. 24 
